Metcela
Japan - KanagawaBiotechnology
Focus: Metcela is a Japanese biotechnology company focused on cell therapy and gene therapy, founded in 2016 and based in Kanagawa. The company is advancing a single Phase 3 program in autologous cardiac stem cells for a rare pediatric heart condition.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Metcela
AI assessmentNot HiringNo open roles listed right now. Follow Metcela to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Autologous cardiac stem cells
Hypoplastic Left Heart SyndromeClinical Trials (1)
NCT02781922Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
Phase 3Help build intelligence for Metcela
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.